Halozyme Therapeutics, Inc. 8-K Filing
Ticker: HALO · Form: 8-K · Filed: Nov 24, 2025 · CIK: 1159036
| Field | Detail |
|---|---|
| Company | Halozyme Therapeutics, Inc. (HALO) |
| Form Type | 8-K |
| Filed Date | Nov 24, 2025 |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Halozyme Therapeutics, Inc. (ticker: HALO) to the SEC on Nov 24, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Market).
How long is this filing?
Halozyme Therapeutics, Inc.'s 8-K filing is 3 pages with approximately 819 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 819 words · 3 min read · ~3 pages · Grade level 13.4 · Accepted 2025-11-24 16:06:34
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Market
Filing Documents
- halo-20251118.htm (8-K) — 32KB
- halo-20251118_g1.jpg (GRAPHIC) — 15KB
- 0001159036-25-000061.txt ( ) — 173KB
- halo-20251118.xsd (EX-101.SCH) — 2KB
- halo-20251118_lab.xml (EX-101.LAB) — 21KB
- halo-20251118_pre.xml (EX-101.PRE) — 12KB
- halo-20251118_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Halozyme Therapeutics, Inc. (Registrant) Dated: November 24, 2025 By: /s/ Mark Snyder Mark Snyder Senior Vice President, General Counsel and Corporate Secretary